Event free survival is prolonged by maintenance therapy with lenalidomide. Continuous chemotherapy plus novel agents for a better response rate, with far more personalized therapy in the form of dose adjustment, in order to manage toxicities.
Maintain and control the disease from the diagnosis, to the remission.

Prof Boccadoro also discusses a session he chaired on under 65 myeloma patients and auto-transplants; updating on the best treatment for younger myeloma patients. Response rates are better before and after transplant and again maintenance therapy is important.

Prof Boccadoro further discusses a session which took place on second primary malignancies, where patients treated for a long period of time have had secondary leukaemias.

Speaking at the International Myeloma Workshop, Paris, 5th May 2011.